Esperion Therapeutis.Inc. sell Bank of America Co.
Start price
20.06.24
/
50%
€2.36
Target price
20.06.25
€2.33
Performance (%)
-4.37%
Price
22:26
€2.26
Summary
This prediction is currently active. With a performance of -4.37%, the SELL prediction by Bank_of_America_Co_ is trending in the right direction. This prediction currently runs until 20.06.25. The prediction end date can be changed by Bank_of_America_Co_ at any time. Bank_of_America_Co_ has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Esperion Therapeutis.Inc. | 1.625% |
| iShares Core DAX® | 1.133% |
| iShares Nasdaq 100 | 0.815% |
| iShares Nikkei 225® | 1.990% |
| iShares S&P 500 | -0.014% |
Comments by Bank_of_America_Co_ for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was downgraded by analysts at Bank of America Co. from a "neutral" rating to an "underperform" rating. They now have a $2.50 price target on the stock, down previously from $2.90.
Ratings data for ESPR provided by MarketBeat
Stopped prediction by Bank_of_America_Co_ for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
Start price
Target price
Perf. (%)
€1.27
15.06.23
15.06.23
€3.68
15.06.24
15.06.24
111.30%
16.06.24
16.06.24
